Peritonitis

Kanamycin (Kanamycin A) is an antibacterial agent. Kanamycin blocks Kir4.1 channels. Kanamycin inhibits bacterial mRNA translation and exerts bactericidal effects against Gram-positive, Gram-negative, and acid-resistant microorganisms. Kanamycin produces ROS and superoxide and induces caspase-3-mediated apoptosis. Kanamycin inhibits biofilms and reduces persister bacteria, and reduces Mycobacterium tuberculosis within macrophages. Kanamycin can be used in research on bacterial infections, urinary tract infections, tuberculosis, and Staphylococcus aureus-induced peritonitis.

Kanamycin sulfate (Kanamycin A sulfate) is an antibacterial agent. Kanamycin sulfate blocks Kir4.1 channels. Kanamycin sulfate inhibits bacterial mRNA translation and exerts bactericidal effects against Gram-positive, Gram-negative, and acid-resistant microorganisms. Kanamycin sulfate produces ROS and superoxide and induces caspase-3-mediated apoptosis. Kanamycin sulfate inhibits biofilms and reduces persister bacteria, and reduces Mycobacterium tuberculosis within macrophages. Kanamycin sulfate can be used in research on bacterial infections, urinary tract infections, tuberculosis, and Staphylococcus aureus-induced peritonitis.

Zymosan A (Zymosan A from Saccharomyces cerevisiae) is a TLR2 agonist, that targeting TLRs can prevent and suppress IR-induced intestinal injury. Zymosan A exhibits a significant radioprotective effect, and protects IR-induced intestinal injury in mice. Zymosan A promotes the regeneration of intestinal stem cells (ISCs), after IR injury.

Cefotaxime, a β-lactamase stable cephalosporin and a third-generation cephalosporin antibiotic, possesses broad-spectrum antibiotic activity against numerous Gram-positive and Gram-negative bacteria.

AS-252424 is a potent and selective PI3Kγ inhibitor with an IC₅₀ of 30±10 nM.

NP3-253 is an orally active and brain-penetranted NLRP3 inflammasome inhibitor. NP3-253 functions as a molecular glue that prevents NACHT-subdomain rearrangements, locking NLRP3 in an inactive conformation. NP3-253 inhibits production of pro-inflammatory cytokines IL-1β and IL-18. NP3-253 can be used for the research of inflammation and neurological disease, suah as peritonitis.

EC144 is an orally active and selective Hsp90 inhibitor (IC₅₀ = 1.1 nM, K_i = 0.2 nM). EC144 inhibits NLRP3 inflammasome (IC₅₀ 99 nM), binds to the ATP-binding pocket of the N-terminal domain, blocks chaperone function and destabilizes client proteins, including JAK2, STAT3, Her-2, EGFR, IGFR, Akt, ErbB2 and cyclin D, with higher selectivity for cytoplasmic Hsp90 than for Grp94 and TNF-α-inducible protein 1 (TNFAIP1). EC144 also directly binds to the extracellular region of E-cadherin, disrupting E-cadherin-mediated adhesion and tight junction function, and exhibits species-specific binding to human, bovine and mouse E-cadherin, but does not bind rat or chicken E-cadherin, and does not interact with N-cadherin or VE-cadherin. EC144 blocks NLRP3 inflammasome priming and activation, ASC speck formation, caspase-1 activation, IL-1β release and pyroptotic cell death. EC144 is detectable at brain levels after oral administration and upregulates brain Hsp70. EC144 can be used for research on rheumatoid arthritis, Alzheimer's disease, intervertebral disc degeneration, peritonitis, gastric cancer and botulism.

Resolvin E2 ((-)-Resolvin E2) is an endogenous lipid mediator produced from eicosapentaenoic acid (EPA) under the catalysis of 5-lipoxygenase (5-LOX), and its production increases in hypoxic environments. Resolvin E2 antagonizes BLT1, partially activates ChemR23, and promotes ubiquitin-proteasome-mediated degradation of COX-2. Resolvin E2 reduces the production of prostaglandin E₂, blocks polymorphonuclear leukocyte infiltration, and promotes the resolution of airway inflammation. Resolvin E2 ameliorates lipopolysaccharide (LPS) (HY-D1056)-induced depressive-like behaviors. Resolvin E2 can be used in research related to depression, murine peritonitis, neonatal asthma, and other conditions.
The product specifications provided below refer solely to the active content of Resolvin E2.

Oleoyl-2-hydroxy-sn-glycero-3-phospho-L-serine sodium (18:1 Lyso-PS) is a modified PS product generated following NADPH oxidase activation and Lyso-PS signal transduction. 1-Oleoyl-2-hydroxy-sn-glycero-3-phospho-L-serine sodium signals through macrophage G2A to enhance the phagocytic uptake of PS-dependent apoptotic (apoptosis) neutrophils and PS-exposed activated neutrophils. 1-Oleoyl-2-hydroxy-sn-glycero-3-phospho-L-serine sodium enhances macrophage phagocytic uptake of apoptotic cells, carboxylate-modified microspheres, and PS-exposed non-apoptotic activated neutrophils. 1-Oleoyl-2-hydroxy-sn-glycero-3-phospho-L-serine sodium serves as an acyl acceptor substrate for the lysophosphatidyltransferase At1g78690p to generate diacylphosphatidylserine. 1-Oleoyl-2-hydroxy-sn-glycero-3-phospho-L-serine sodium reduces the secretion of IL-8 and decreases the proportion of viable colon cancer cells. 1-Oleoyl-2-hydroxy-sn-glycero-3-phospho-L-serine sodium is applicable to studies on peritonitis and inflammatory bowel disease.

Ac5GalNTGc is a potent, peracetylated C-2 thioglycolyl-substituted GalNAc analog that efficiently inhibits mucin-type O-glycan biosynthesis. Ac5GalNTGc reduces leukocyte sialyl-Lewis-X expression and inhibits L-/P-selectin mediated rolling under flow, as well as P-selectin dependent leukocyte-platelet adhesion. Ac5GalNTGc exhibits anti-inflammatory activity in a thioglycollate-induced acute peritonitis model. Ac5GalNTGc can be used for studies of O-glycan/mucin biology, inflammation, and related translational research.

ZY39 is a SaClpP agonist. ZY39 promotes the enzymatic hydrolysis of SaClpP and HsClpP in vitro. ZY39 inhibits the growth of Staphylococcus aureus strains. ZY39 reduces the load of Staphylococcus aureus in organs and ascites in mouse peritonitis models and zebrafish infection models, and improves the survival rate of model animals. ZY39 can be used in studies related to Staphylococcus aureus infection, such as peritonitis.

Kanamycin disulfate (Kanamycin A disulfate) is an antibacterial agent. Kanamycin disulfate blocks Kir4.1 channels. Kanamycin disulfate inhibits bacterial mRNA translation and exerts bactericidal effects against Gram-positive, Gram-negative, and acid-resistant microorganisms. Kanamycin disulfate produces ROS and superoxide and induces caspase-3-mediated apoptosis. Kanamycin disulfate inhibits biofilms and reduces persister bacteria, and reduces Mycobacterium tuberculosis within macrophages. Kanamycin disulfate can be used in research on bacterial infections, urinary tract infections, tuberculosis, and Staphylococcus aureus-induced peritonitis.

PROTAC BTK Degrader-6 is an orally active PROTAC-based BTK degrader with a DC₅₀ of 3.18 nM. PROTAC BTK Degrader-6 induces BTK degradation via proteasomal degradation, ubiquitination, and CRBN ligase recruitment pathways. PROTAC BTK Degrader-6 inhibits NF-κB activation, mRNA expression of IL-1β and IL-6, as well as the secretion of pro-inflammatory cytokines. PROTAC BTK Degrader-6 reduces inflammatory responses in a zymosan-induced mouse model of peritonitis. PROTAC BTK Degrader-6 can be used in peritonitis-related research.

PAV-104 (MAV-104) is a host-targeted, pan-respiratory viral assembly inhibitor. PAV-104 targets a small subset of the host protein 14-3-3 within a transient multi-protein complex. PAV-104 inhibits SARS-CoV-2 replication by blocking post-entry viral assembly/budding through interaction with viral nucleocapsid (N) protein and interference with its oligomerization. PAV-104 is orally active in cats and shows favorable pharmacokinetic properties in rats. PAV-104 can be used for the study of COVID-19 and other respiratory viral infections, including Feline Infectious Peritonitis (FIP).

Kanamycin (Standard) (Kanamycin A (Standard)) is the analytical standard of Kanamycin (HY-16566). This product is intended for research and analytical applications. Kanamycin (Kanamycin A) is an antibacterial agent. Kanamycin blocks Kir4.1 channels. Kanamycin inhibits bacterial mRNA translation and exerts bactericidal effects against Gram-positive, Gram-negative, and acid-resistant microorganisms. Kanamycin produces ROS and superoxide and induces caspase-3-mediated apoptosis. Kanamycin inhibits biofilms and reduces persister bacteria, and reduces Mycobacterium tuberculosis within macrophages. Kanamycin can be used in research on bacterial infections, urinary tract infections, tuberculosis, and Staphylococcus aureus-induced peritonitis.

Apidaecin IA is a basic peptide. Apidaecin IA inhibits the enzymatic activity of DnaK. Apidaecin IA induces bacterial cell death. Apidaecin IA can be used in research related to peritonitis and bacterial infections.

17(R)-Protectin D1 (17-epi-Protectin D1) is a protectin-family-specific pro-resolving lipid mediator derived from DHA (HY-B2167) and generated via Aspirin (HY-14654) triggering, possessing pro-inflammatory resolution, neuroprotective, and other activities. 17(R)-Protectin D1 is also the 17R-epimer of Protectin D1 (HY-130413). 17(R)-Protectin D1 enhances macrophage phagocytosis of Escherichia coli and limits neutrophil infiltration. 17(R)-Protectin D1 attenuates stroke severity in animal models. 17(R)-Protectin D1 can be used in research related to peritonitis and stroke.

12 (S)-HEPE is an oxidation product of Eicosapentaenoic acid (HY-B0660). 12 (S)-HEPE activates p38α, GSKβ, CREB, and ERK1/2. 12 (S)-HEPE induces DNA synthesis. 12 (S)-HEPE leads to activation of the PI3K-mTORC2-Akt signaling pathway and translocation of Glut4 to the plasma membrane. 12 (S)-HEPE increases glucose uptake. 12 (S)-HEPE reduces body weight gain in HFD mice. 12 (S)-HEPE can be used in research on colorectal cancer, zymosan-induced peritonitis, diabetes, and obesity.
The product specifications provided below refer solely to the active content of 12(S)-HEPE.

2-ARA-LysoPtdEtn (1-Lyso-2-arachidonoyl-sn-glycero-3-phosphoethanolamine) is an orally active polyunsaturated acyl lysophosphatidylethanolamine. 2-ARA-LysoPtdEtn diminishes formation of LTC₄, LTB₄, and 12-HETE. 2-ARA-LysoPtdEtn lowers levels of IL-1β, IL-6, TNF-α, and NO. 2-ARA-LysoPtdEtn augments IL-10 levels and upgrades formation of 15-HETE and LXA₄. 2-ARA-LysoPtdEtn can be used for the research of peritonitis.

EBL‑3599 is an LpxH inhibitor derived from JEDI‑852 and JEDI‑1444 (HY-187940). EBL-3599 exhibits antibacterial activity against E. coli, K. pneumoniae, and efflux-deficient A. baumannii, P. aeruginosa, and P. mirabilis. EBL-3599 exhibits dose-dependent in vivo efficacy against E. coli and K. pneumoniae in a mouse peritonitis model. EBL-3599 can be used for research on bacterial infections and peritonitis.